In the TCGA data, HCC patients with SOD2 low mRNA expression is significantly associated with much shorter OS (p < 0.034) and RFS (p < 0.028) in HCCs with mutant TP53 than those with wild type TP53. Further study the relationship between p53 and SOD2 could lead to insights into the pathogenesis of liver cancer and may lead to new approaches to HCC prevention and therapy. This evidence concerns the gene SOD2 and liver cancer.